Results from a five-year Investigational Device Exemption study of 261 patients indicate that Aesculap Implant Systems’ activL® lumbar disc more effectively preserved range of motion vs. the ProDisc-L and Charité, first-generation lumbar total disc replacement devices.
Secondary outcomes suggest that activeL was effective in reducing back pain, improving back function and increasing health-related quality of life. Further, at five years, 95% of activL subjects were re-operation free vs. fusion.
Results from a five-year Investigational Device Exemption study of 261 patients indicate that Aesculap Implant Systems' activL® lumbar disc more effectively preserved range of motion vs. the ProDisc-L and Charité, first-generation lumbar total disc replacement devices.
Secondary outcomes suggest that activeL was effective in reducing back...
Results from a five-year Investigational Device Exemption study of 261 patients indicate that Aesculap Implant Systems’ activL® lumbar disc more effectively preserved range of motion vs. the ProDisc-L and Charité, first-generation lumbar total disc replacement devices.
Secondary outcomes suggest that activeL was effective in reducing back pain, improving back function and increasing health-related quality of life. Further, at five years, 95% of activL subjects were re-operation free vs. fusion.
Copy to clipboard 
